![Mark Vickery Mark Vickery](https://staticx.zacks.com/images/mugshots/mark_vickery/mark_vickery-8.png)
Top Research Reports for May 4, 2017
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thursday May 4, 2017
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).
Exxon Mobil shares tracked the S&P 500 index through year-end 2016, but have lagged the broader index as well as the peer super majors group in the year-to-date period, likely reflecting the company's perceived defensiveness that disadvantages it relative to its 'oilier' peers. During first-quarter 2017, the company posted strong earnings on the back of increased realizations for liquids and gas as well as higher margin from the downstream business.
Exxon's resilient integrated business model has long been the industry gold standard, which makes it an attractive and relatively low-risk Energy sector option for many investors. A fortress balance sheet, an attractive and totally safe dividend and a history of returning excess cash to shareholders are some of the other positives in the Exxon story.
The Zacks analyst discusses the pros and cons of investing in Exxon shares in the updated research report issued today. (You can read the full research report on Exxon Mobil here.)
Shares of JPMorgan have gained +24.5% over the past six months vs. +23.9% gain for the Major Banks industry. The company’s first-quarter 2017 earnings easily outpaced expectations driven by impressive investment banking and trading revenue growth as well as lower credit costs.
The Zacks analyst likes the company’s has steady capital deployment activities (dividend hike and share buyback), which reflects its strong balance sheet position. The company remains well positioned to benefit from the improved rate scenario and rising loan demand. Synergies from retail banking performance and cost-containment efforts will help improving its profitability, going forward.
However, a persistent fee income growth challenge remains a major headwind. Also, litigation hassles remain a concern. (You can read the full research report on JPMorgan here.)
Union Pacific shares have rallied 3.8% in the last month, outperforming the Zacks Transportation-Rail industry’s increase of 3.66% in the period. Shares of Union Pacific have also performed better than those of fellow-railroad operator Norfolk Southern, which have gained 2.2% in the same time span.
Union Pacific reported better-than-expected earnings and revenues in the first quarter of 2017. The improvement in coal revenues and the company's 2017 capital plan worth $3.1 billion are other positives. The plan complements the company's efforts to promote safety and enhance productivity. The below-par performance of the automotive unit in the first quarter, however, raises concerns. (You can read the full research report on Union Pacific here.)
Other noteworthy reports we are featuring today include Biogen (BIIB), ADP (ADP) and Becton Dickinson (BDX).
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
Get the latest research report on JPM - FREE
Get the latest research report on BIIB - FREE
Get the latest research report on ADP - FREE
Get the latest research report on XOM - FREE
Get the latest research report on UNP - FREE
Get the latest research report on BDX - FREE